Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.79 [0.62, 1.02] | | < 1 | | 0% | 2 studies (2/-) | 96.6 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.71 [0.45, 1.12] | | < 1 | | 0% | 1 study (1/-) | 92.9 % | NA | not evaluable | | important | - |
PFS (extension) | 0.54 [0.35, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.68 [0.52, 0.88] | | < 1 | | 9% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 3.06 [1.45, 6.45] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
objective responses (ORR) (extension) | 2.80 [1.34, 5.83] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
STRAE (any grade) | 2.15 [1.17, 3.97] | | < 1 | | 24% | 2 studies (2/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 2.83 [1.13, 7.06] | | < 1 | | 45% | 2 studies (2/-) | 1.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 1.99 [0.57, 6.90] | | < 1 | | 71% | 2 studies (2/-) | 14.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 2.28 [1.56, 3.32] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.60 [0.20, 12.77] | | < 1 | | 38% | 2 studies (2/-) | 33.1 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.86 [0.50, 1.46] | | < 1 | | 0% | 2 studies (2/-) | 71.4 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 1.35 [0.29, 6.37] | | < 1 | | 51% | 2 studies (2/-) | 35.2 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 4.32 [0.19, 97.73] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 1.19 [0.71, 1.97] | | < 1 | | 0% | 2 studies (2/-) | 25.6 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 1.06 [0.07, 17.15] | | < 1 | | 0% | 1 study (1/-) | 48.3 % | NA | not evaluable | | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.45 [0.04, 5.14] | | < 1 | | 0% | 2 studies (2/-) | 73.9 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 1.37 [0.33, 5.63] | | < 1 | | 0% | 2 studies (2/-) | 33.0 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.89 [0.16, 4.91] | | < 1 | | 0% | 2 studies (2/-) | 55.3 % | some concern | not evaluable | moderate | non important | - |
Dizziness TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 2.39 [0.77, 7.43] | | < 1 | | 0% | 2 studies (2/-) | 6.7 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
Increased lacrimation (TRAE grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.96 [0.28, 3.31] | | < 1 | | 0% | 2 studies (2/-) | 52.8 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 1.24 [0.67, 2.28] | | < 1 | | 0% | 2 studies (2/-) | 24.9 % | some concern | not evaluable | moderate | non important | - |
Pancytopenia TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.06 [0.07, 17.04] | | < 1 | | 0% | 2 studies (2/-) | 48.4 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 2.13 [0.19, 23.68] | | < 1 | | 0% | 2 studies (2/-) | 27.1 % | some concern | not evaluable | moderate | non important | - |
Sepsis TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.05 [0.14, 7.73] | | < 1 | | 0% | 1 study (1/-) | 48.0 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 1.52 [0.38, 6.07] | | < 1 | | 0% | 2 studies (2/-) | 27.6 % | some concern | not evaluable | moderate | non important | - |